The estimated Net Worth of Fund Iv, L.P.Omega Fund Iv ... is at least $61.4 Milion dollars as of 14 March 2022. Fund Iv owns over 106,500 units of Replimune Inc stock worth over $48,462,951 and over the last 5 years Fund sold REPL stock worth over $12,964,195.
Fund has made over 15 trades of the Replimune Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Fund sold 106,500 units of REPL stock worth $1,656,075 on 14 March 2022.
The largest trade Fund's ever made was buying 220,000 units of Replimune Inc stock on 18 November 2019 worth over $2,994,200. On average, Fund trades about 42,700 units every 56 days since 2019. As of 14 March 2022 Fund still owns at least 4,673,380 units of Replimune Inc stock.
You can see the complete history of Fund Iv stock trades at the bottom of the page.
Over the last 6 years, insiders at Replimune Inc have traded over $72,652,546 worth of Replimune Inc stock and bought 2,360,000 units worth $33,565,200 . The most active insiders traders include Group, Llc Green Jeremy Red..., Capital Life Sciences Inves... a Jason P Rhodes. On average, Replimune Inc executives and independent directors trade stock every 21 days with the average trade being worth of $508,649. The most recent stock trade was executed by Emily Luisa Hill on 16 August 2024, trading 8,938 units of REPL stock currently worth $90,989.
replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.
Replimune Inc executives and other stock owners filed with the SEC include: